The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

Bullous pemphigoid (BP) is an acquired disease that belongs to the group of autoimmune subepidermic bullous disorders. It features circulating autoantibodies against distinctive skin's basal membrane ...